

SAFETY AND EFFICACY OF ENDOSCOPIC ULTRASOUND- GUIDED RADIOFREQUENCY ABLATION FOR PANCREATIC INSULINOMA: A SINGLE-CENTER EXPERIENCE

Fabia Attili

UEG Week Copenhagen 2023

Poster

Pancreas

October 15, 2023

A retrospective case series of 10 patients with pancreatic insulinoma treated with EUS-guided radiofrequency ablation demonstrated 100% technical success, immediate euglycemia, and complete radiological response with minimal adverse events.

KEY POINTS

- All 10 patients (mean age 67.1 years, mean tumor size 11.9 mm) who were unfit for surgery or refused surgery achieved technical success, immediate post-procedural euglycemia, and complete radiological response by CT scan within 90 days
- The procedure used a 19G RFA needle with 20-50W energy, median 6 passes, and median 15 seconds ablation duration per pass
- Early adverse events were mild abdominal pain in 2 patients (20%) and bleeding in 1 patient (10%), with no late adverse events
- Persistent clinical remission was maintained at 6 months (10/10 patients) and 12 months (9/9 patients available for follow-up)
- The authors conclude EUS-RFA may be feasible and safe for pancreatic insulinomas with mid-term efficacy; this series is relevant for clinicians managing patients unsuitable for surgical resection

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/05bc04d0-743c-11ee-96c1-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.